Schöffski, P.

(Patrick Schöffski)

patient cancer treatment docetaxel study -014813 phase su -014813 cycle trial inhibitor kinase response phase ii trial european grade disease ﬁ rst protocol dose level pharmacokinetic tissue sarcoma tumour combination plasma melanoma european organization neck cancer day 1 polo-like concentration core institutes breast cancer fatigue event course sarcoma level tissue toxicity article journal research press breast table activity neutropenia 75 mg /m oncol survival tumours sunitinib therapy blood neutropaenia neutropenic fever protocol organization phase ii studies infusion press european journal eortc progression-free survival anti-tumour activity agent novel schedule network diarrhoea institutes growth 3 patients multicentric ﬂ uid pressure assessment factor fever 200 mg delay anti-tumour

2 Most Recent Publications

Phase i safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours (Article)
Jonge, M.J.A. de Dumez, H. Kitzen, J.J.E.M. Beuselinck, B. Verweij, J. Courtney, R. Battista, A. Brega, N. Schöffski, P.

2011-06-01

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) (Article)
Schöffski, P. Blay, J-Y. Munzert, G. Fritsch, H. Hanft, G. Aerts, C. Rapion, J. Allgeier, A. Bogaerts, J. Lacombe, D. Greve, J. de Brain, E. Machiels, J. Soria, J.C. Sleijfer, S. Wolter, P. Ray-Coquard, I. Fontaine, C.

2010-05-14

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.